We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
The pathological finding of this case was renal metastasis from prostaticadenocarcinoma.
2
Conclusions: We found that the prostaticadenocarcinoma among Sudanese patients was less aggressive.
3
Secretagogin is widely expressed in prostaticadenocarcinoma as opposed to adenocarcinomas in other organs.
4
Brachytherapy can represent the exclusive treatment of localized prostaticadenocarcinoma.
5
Results: The resultant tissue displayed a phenotype consistent with a poorly differentiated human prostaticadenocarcinoma.
6
Presenting symptom of the prostaticadenocarcinoma patient was symptomatic hypoglycaemia which resolved completely after IPP.
7
Coumarin has shown activity against prostatic carcinoma in the Dunning R-3327 rat prostaticadenocarcinoma model.
8
An increase in Ki67-positive cells appeared in all mPIN and prostaticadenocarcinoma lesions of the mice.
9
In one patient the renal tumour was found when examined on follow-up examination for prostaticadenocarcinoma.
10
The establishment of a new prostate cell line (BM1604) from a human prostaticadenocarcinoma is reported.
11
Our results stated that prostaticadenocarcinoma among Sudanese patients was of low grade which means tumours are less aggressive.
12
Methods and materials: Paraffin-embedded prostaticadenocarcinoma material was obtained from patients treated from 1987-1991.
13
Twenty-one patients with advanced prostaticadenocarcinoma previously untreated with conventional endocrine therapy were treated with an oral non-steroidal antiandrogen, flutamide.
14
Introduction: Metastatic prostaticadenocarcinoma (PAC) has mostly involved the pelvic lymph nodes; metastases to the cervical lymph nodes are exceedingly rare.
15
We retrospectively reviewed records of 551 patients with clinical Stage C prostaticadenocarcinoma treated with 60 to 70 Gy external beam radiation.
16
Methods and materials: Between November 1991 and February 1994, 99 implants were performed on 33 patients with prostaticadenocarcinoma at William Beaumont Hospital.